StockNews.AI
TBPH
StockNews.AI
117 days

Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

1. TBPH to report Q1 2025 results on May 8, 2025. 2. Conference call scheduled for 5:00 pm EDT. 3. Focus on shareholder value and successful therapies emphasized. 4. YUPELRI® for COPD patients is a key product. 5. Ampreloxetine targets neurogenic orthostatic hypotension treatment.

Earnings
+0.26%Current Return
VS
+2.41%S&P 500
$9.4504/24 06:21 AM EDTEvent Start
$9.47504/25 12:30 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Neutral?

The upcoming earnings report may not significantly sway investor sentiment. Similar earnings reports previously showed stable stock behavior.

How important is it?

The Q1 report may disclose critical insights into TBPH's financial health and future outlook.

Why Short Term?

Earnings releases typically have immediate but short-lived impacts. Market reaction often occurs around earnings dates without lasting effects.

Related Companies

AMGNGILDVRTX
, /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2025 financial results and provide a business update after market close on Thursday, May 8, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EDT (2:00 pm PDT/10:00 pm IST) that day. Conference Call Information To participate in the live call by telephone, please dial (800) 715-9871 from the US or (646) 307-1963 for international callers, using the Conference ID 3369474. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, under the Investors section, Events and Presentations. A replay of the webcast will be available on Theravance Biopharma's website for 30 days through June 7, 2025. About Theravance Biopharma Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value. For more information, please visit www.theravance.com. THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners. Contact:[email protected]650-808-4045 SOURCE Theravance Biopharma, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News